Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1111086 | 0.98 | CTSK (0.38) | CTSKCTSSSOS2TRPV4SRC | |
| SCHEMBL2960222 | 0.84 | CTSK (0.41) | CTSKCTSSSOS2TRPV4SRC | |
| SCHEMBL24794162 | 0.81 | CTSS (0.49) | CTSKCTSSSOS2SRCIRAK4 | |
| SCHEMBL1273797 | 0.79 | IRAK4 (0.37) | IRAK4IDH1 | |
| SCHEMBL19309204 | 0.78 | BRS3 (0.40) | CTSKCTSSSOS2TRPV4SRC | |
| SCHEMBL24608472 | 0.77 | SOS2 (0.38) | CTSKCTSSSOS2SRCEGLN2 | |
| SCHEMBL24608476 | 0.77 | CTSK (0.36) | CTSKCTSSSOS2TRPV4SRC | |
| SCHEMBL1442844 | 0.76 | CTSS (0.51) | CTSKCTSSSOS2IRAK4IDH1 | |
| SCHEMBL30449276 | 0.76 | CTSS (0.51) | CTSKCTSSSOS2IRAK4IDH1 | |
| SCHEMBL19646337 | 0.75 | CTSS (0.36) | CTSKCTSSSOS2SRCEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426448-B2 | 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | ELI LILLY AND COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426448-B2 | 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | ELI LILLY AND COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426448-B2 | 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | ELI LILLY AND COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| CN-102119029-B | 1, 5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | LILLY CO ELI | 2013-03-13 | — | — | CN | disclosed |
| CN-102119029-A | 1, 5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | LILLY CO ELI | 2011-07-06 | — | — | CN | disclosed |
| US-20110028520-A1 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | ELI LILLY AND COMPANY (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028520-A1 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | ELI LILLY AND COMPANY (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028520-A1 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | ELI LILLY AND COMPANY (US) | 2011-02-03 | — | — | US | disclosed |
| EP-2278968-A2 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | ELI LILLY AND COMPANY (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009131814-A2 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | ELI LILLY AND COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009131814-A2 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | ELI LILLY AND COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| US-5371097-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5364871-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028520-A1 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | CNR1, CNR2, GPR119 | CTSK 2364/4885CTSS 1468/4885SOS2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.